Publications by authors named "Hisashi Hosaka"

Article Synopsis
  • The study focused on identifying biomarkers that can predict treatment outcomes and immune-related adverse events in patients with advanced recurrent gastric cancer receiving chemotherapy and nivolumab.
  • The research involved 104 patients, analyzing blood tests before and after treatment to assess changes in specific ratios like the lactate dehydrogenase/albumin ratio (LAR).
  • Results showed that 54.8% of patients had a positive response to treatment and that the LAR could serve as a potential biomarker for therapeutic response and efficacy.
View Article and Find Full Text PDF
Article Synopsis
  • A multicenter study analyzed data from 104 patients with unresectable advanced or recurrent gastric cancer, focusing on conversion surgery (CS) after chemotherapy plus nivolumab as first-line treatment.
  • Out of the patients, 12 (11.5%) underwent CS, with significantly better Eastern Cooperative Oncology Group Performance Status (ECOG-PS) in those who did compared to those who did not.
  • The study found no high-risk Gustave Roussy Immune Score (GRIm-s) cases among those who had CS, suggesting that the GRIm-s might serve as a predictive biomarker for successful surgery outcomes.
View Article and Find Full Text PDF
Article Synopsis
  • A study was conducted to evaluate the effectiveness and safety of Capecitabine plus oxaliplatin (CapeOX) as a first-line treatment for advanced gastric cancer in patients aged 70 years and older.
  • The trial included 108 chemotherapy-naive patients, who were given either the original or reduced doses of CapeOX, with overall survival (OS) being the primary measurement.
  • Results showed a median OS of 12.9 months, with some patients experiencing significant side effects, mainly neutropenia and anemia, indicating that CapeOX is a viable treatment option for older patients with advanced gastric cancer.
View Article and Find Full Text PDF

Background/aim: Establishment of powerful and easy-to-evaluate biomarkers that can predict immune checkpoint inhibitor sensitivity in patients with gastric cancer (GC) would be highly useful. The albumin-derived neutrophil-to-lymphocyte ratio (Alb-dNLR) score reportedly is an excellent measure of both immunity and nutritional status. However, the association between nivolumab treatment sensitivity and Alb-dNLR in GC has also not been adequately investigated.

View Article and Find Full Text PDF

Background/aim: To discover the positive therapeutic effects of nivolumab in patients with advanced gastric cancer (AGC), it is necessary to establish a useful biomarker to predict therapeutic efficacy. This multicenter retrospective study sought to evaluate the predictive impact of inflammation-based prognostic score (IBPS) on the therapeutic efficacy of nivolumab in patients with AGC.

Patients And Methods: In this retrospective study, we evaluated 58 AGC patients treated with nivolumab from October 2017 to November 2018 at five institutes.

View Article and Find Full Text PDF

Background: Identification of positive biomarkers for the effects of nivolumab on patients with advanced gastric cancer (AGC) is significant. The Gustave Roussy Immune Score (GRIm-s) is associated with therapeutic resistance of immune checkpoint inhibitors (ICIs) in other cancers. This multicenter, retrospective study was designed to analyze the association of GRIm-s with therapeutic sensitivity of nivolumab in patients with AGC.

View Article and Find Full Text PDF

Introduction: This retrospective study investigated the efficacy and safety of nano-liposomal irinotecan (nal-IRI) plus 5-fluorouracil/L-leucovorin (5-FU/l-LV) treatment in the second-line or later setting for advanced pancreatic cancer under real-world conditions.

Methods: Between June 2020 and September 2021, a total of 44 patients with unresectable advanced pancreatic cancer treated with nal-IRI + 5-FU/l-LV in our affiliated hospitals were included. The prognosis, predictive factors (including systemic inflammation-based prognostic indicators), and adverse events were investigated.

View Article and Find Full Text PDF

The KEYNOTE-659 study evaluated the efficacy and safety of first-line pembrolizumab plus S-1 and oxaliplatin (SOX) (cohort 1) or S-1 and cisplatin (SP) (cohort 2) for advanced gastric/gastroesophageal junction (G/GEJ) cancer in Japan. Herein, we update the results of cohort 1 and describe the results of cohort 2. This open-label phase IIb study enrolled patients with advanced programmed death-ligand 1 (PD-L1)-positive (combined positive score ≥ 1) human epidermal growth factor receptor 2 (HER2)-negative G/GEJ adenocarcinoma.

View Article and Find Full Text PDF

Background: Safety of combination chemotherapy using platinum and fluorouracil has not been evaluated adequately for advanced gastric cancer (AGC) in elderly patients.

Patients And Methods: We initiated a phase II study to evaluate the efficacy and safety of capecitabine plus oxaliplatin (CapeOX) as first-line therapy for patients with AGC aged ≥70 years. Planned assessment of toxicity was made upon recruitment of the first 20 patients.

View Article and Find Full Text PDF

Background: Trifluridine and tipiracil (FTD/TPI) demonstrated survival benefit vs placebo and manageable safety in previously treated patients with metastatic gastric/gastroesophageal junction cancer (mGC/GEJC) in the randomized, placebo-controlled, phase 3 TAGS study. This subgroup analysis of TAGS examined efficacy/safety outcomes by age.

Methods: In TAGS, patients with mGC/GEJC and ≥ 2 prior therapies were randomized (2:1) to receive FTD/TPI 35 mg/m or placebo, plus best supportive care.

View Article and Find Full Text PDF

Background: Although nivolumab (anti-programmed cell death-1 antibody) is a promising approach for advanced gastric cancer (AGC), the response rate remains limited. The aim of this multicenter retrospective study was to determine if clinical features could serve as prognostic factors of the efficacy of nivolumab in patients with AGC.

Methods: Fifty-eight patients with AGC who were treated with nivolumab as a third or later line from October 2017 to December 2018 at any of five clinical sites were enrolled in the study.

View Article and Find Full Text PDF

: Seasonal climatic changes may affect the development of the rash that is characteristic of treatment with anti-epidermal growth factor receptor (EGFR) antibodies. We evaluated the association between seasons and rash incidence among patients with cancer. : Data from patients with colorectal or head and neck cancer treated with cetuximab or panitumumab during summer (S group; = 34) or winter (W group; = 37) between June 2014 and February 2019 were collected to retrospectively examine patient characteristics and rash incidence ≤ 8 weeks after treatment initiation.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates FGFR2 as a potential target for treatment in patients with unresectable gastric cancer, emphasizing its link to poor prognosis post-chemotherapy.
  • Researchers analyzed tissue samples from Japanese patients to assess the frequency of FGFR2 overexpression and gene amplification using specialized staining methods.
  • Results revealed FGFR2 alterations in many cases, but these changes did not significantly affect the patients' responses to first-line chemotherapy.
View Article and Find Full Text PDF

Pyogenic granuloma (PG) is a granulomatous elevated lesion that occurs on the skin and mucous membranes. We herein report two cases of intra-oral PG that developed during the administration of ramucirumab for gastric cancer. Case 1 involved a 55-year-old man with a 6-mm tumor on the right tongue, and case 2 involved a 67-year-old man with a 5-mm tumor on the upper lip.

View Article and Find Full Text PDF

Background: Patients with stage IV gastric cancer have a poor prognosis despite improvements in intensive treatment regimens, including chemotherapy. Recently, conversion surgery has received much attention as it can provide long-term survival in stage IV gastric cancer patients who are responsive to chemotherapy. Herein, we describe the case of a patient who underwent conversion surgery for metastatic gastric cancer that was performed over 2 years after an initial diagnosis of cancer of unknown primary (CUP) with metastasis of the cervical lymph nodes and the ovary.

View Article and Find Full Text PDF

Background: Findings of preclinical and clinical trials in colorectal cancer have shown promising antitumour effects of the co-formulation trifluridine/tipiracil and VEGF inhibition. We aimed to investigate the safety and activity of trifluridine/tipiracil and ramucirumab for previously treated advanced gastric cancer.

Methods: We did an open-label, single-arm, two-cohort, phase 2 study at eight centres in Japan.

View Article and Find Full Text PDF

Background: This study evaluated the association between early tumor response at 8 weeks, previously reported as a positive outcome prognosticator, and health-related quality of life (HRQOL) in advanced gastric cancer (AGC) patients enrolled in the ABSOLUTE trial.

Methods: HRQOL was assessed using the EuroQol-5 Dimension (EQ-5D) utility index score in patients with complete response (CR) + partial response (PR) and progressive disease (PD) at 8 weeks, and time-to-deterioration (TtD) of the EQ-5D score, with the preset minimally important difference (MID) of 0.05, was compared between these populations.

View Article and Find Full Text PDF

Background: S-1 plus leucovorin and oxaliplatin showed promising efficacy for treatment of advanced gastric cancer in a randomised phase 2 study. We aimed to evaluate the efficacy and safety of oral TAS-118 (S-1 plus leucovorin) and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer.

Methods: We did a randomised, open-label, phase 3 trial in 62 centres across Japan and South Korea.

View Article and Find Full Text PDF

Aim: The KEYNOTE-659 study evaluated the efficacy and safety of pembrolizumab in combination with chemotherapy as the first-line treatment in Japanese patients with advanced gastric/gastroesophageal junction (G/GEJ) cancer. In this paper, we report results from cohort 1 (S-1 plus oxaliplatin [SOX] with pembrolizumab).

Methods: This was a non-randomised, multicentre, open-label phase IIb study in patients with advanced programmed death-ligand 1 (PD-L1)-positive, human epidermal growth factor receptor 2-negative G/GEJ tumours.

View Article and Find Full Text PDF

Background: Biweekly irinotecan (CPT-11) plus cisplatin (CDDP) combination (BIRIP) and CPT-11 alone are both expectable options for treating advanced gastric cancer (AGC) in a second-line setting. We conducted a meta-analysis to compare the efficacy and safety of these two regimens in patients enrolled two randomized phase III trials.

Patients And Methods: Individual patient-level data from two randomized phase III trials were collected for this study.

View Article and Find Full Text PDF

Purpose: We compared biweekly irinotecan plus cisplatin (BIRIP) with irinotecan alone as the second-line chemotherapy (SLC) for advanced gastric cancer (AGC).

Methods: Patients with metastatic or recurrent gastric cancer refractory to S-1-based first-line chemotherapy were randomly assigned to receive BIRIP (irinotecan 60mg/m(2) plus cisplatin 30mg/m(2), every 2weeks) or irinotecan alone (irinotecan 150mg/m(2), every 2weeks). The primary end-point was to show the superiority of BIRIP to irinotecan in terms of progression free survival (PFS).

View Article and Find Full Text PDF

Purpose: Cisplatin plus 5-fluorouracil has been globally accepted as a standard regimen for the treatment for advanced gastric cancer. However, cisplatin has several disadvantages, including renal toxicity and the need for admission. S-1 plus cisplatin has become a standard treatment for advanced gastric cancer in East Asia.

View Article and Find Full Text PDF